Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates

This publication has 16 references indexed in Scilit:

• Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture
  Annals of Internal Medicine, 2008
• Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAX^® versus EVISTA^®Comparison Trial) International¹
  Journal of Internal Medicine, 2004
• Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial
  The Journal of Clinical Endocrinology & Metabolism, 2002
• Osteoporosis prevention, diagnosis, and therapy.
  2001
• Comparative Safety of Bone Remodeling Agents with a Focus on Osteoporosis Therapies
  The Journal of Clinical Pharmacology, 2001
• Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled Trial
  JAMA, 1999
• Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical Trial
  JAMA, 1999
• Using Healthcare Claims Data for Outcomes Research and Pharmacoeconomic Analyses
  PharmacoEconomics, 1999
• The worldwide problem of osteoporosis: Insights afforded by epidemiology
  Bone, 1995
• Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
  Journal of Clinical Epidemiology, 1992